Opinion|Videos|November 14, 2024
Current Challenges With Somatostatin Analogues in Neuroendocrine Tumors
Panelists discuss how somatostatin analogues, while effective in controlling hormone-related symptoms and tumor growth in neuroendocrine tumors, face challenges including drug resistance, optimal dosing strategies, and timing of initiation in the treatment sequence.
Advertisement
Advertisement
Related to this article
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Daratumumab Combo Yields Responses in Cardiac-Involved AL Amyloidosis Trials
3
SOHO-02 Trial Will Confirm Sevabertinib’s Frontline NSCLC Benefit
4
Epcoritamab Combo Receives Canadian Approval in R/R Follicular Lymphoma
5